Intellia Therapeutics Announced The Acceptance Of An Abstract Featuring Redosing Data From The Phase 1 Study Of NTLA-2001 Has Been Selected For An Oral Presentation At The Peripheral Nerve Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics announced that an abstract featuring redosing data from the Phase 1 study of NTLA-2001 has been accepted for an oral presentation at the Peripheral Nerve Society Annual Meeting. NTLA-2001 is an investigational CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis.
June 17, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2001 Phase 1 redosing data will be presented at the Peripheral Nerve Society Annual Meeting, highlighting progress in CRISPR-based gene editing for ATTR amyloidosis.
The acceptance of the abstract for an oral presentation at a significant medical meeting suggests positive progress in the development of NTLA-2001. This could boost investor confidence and positively impact NTLA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100